Table 3.
Application of CVVH in patients with IAH
| CVVH N = 60 | No CVVH N = 29 | p | ||
|---|---|---|---|---|
| Demographics | Age, years | 45.1 ± 13.4 | 51.3 ± 16.4 | NS |
| Male, n (%) | 52 (86.7%) | 18 (62.1%) | ||
| Time from the first symptom to hospitalization, median hours (IQR) | 32 (60 to 12) | 24 (34 to 4) | NS | |
| APACHE II at admission, points | 7.9 ± 5.1 | 7.2 ± 4.2 | NS | |
| IAP on admission, mmHg | 15.4 ± 3.7 | 14.5 ± 3.7 | NS | |
| SOFA on admission, points | 2.4 ± 2.2 | 2.0 ± 1.9 | NS | |
| Necrotizing SAP, n (%) | 49 (81.7%) | 16 (55.2%) | 0.01 | |
| MODS, n (%) | 58 (96.7%) | 26% (89.7) | NS | |
| ACS, n (%) | 23 (38.3%) | 10 (34.5%) | NS | |
| Organ dysfunctions | Renal, n (%) | 27 (45%) | 8 (27.6%) | NS |
| Pulmonary, n (%) | 11 (18.3%) | 3 (10.3%) | NS | |
| Liver, n (%) | 6 (10%) | 3 (10.3%) | NS | |
| Cardiovascular, n (%) | 5 (8.3%) | 2 (6.9%) | NS | |
| Hematologic, n (%) | 4 (6.7%) | 3 (10.3%) | NS | |
| Neurologic, n (%) | 15 (25%) | 4 (13.8%) | NS | |
| Complications | Metabolic acidosis, n (%) | 15 (25%) | 2 (6.9%) | 0.05 |
| Pleural effusion, n (%) | 40 (66.7%) | 11 (37.9%) | 0.01 | |
| Pneumonia, n (%) | 28 (46.7%) | 4 (13.8%) | 0.002 | |
| Atelectasis, n (%) | 8 (13.3%) | 2 (6.9%) | NS | |
| Pancreatic/peripancreatic infection, n (%) | 16 (26.7%) | 11 (37.9%) | NS | |
| Surgical intervention, n (%) | 16 (26.7%) | 10 (34.5%) | NS | |